PROKIDNEY CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.68 USD | +14.64% |
|
+5.75% | +106.74% |
| May. 28 | Transcript : ProKidney Corp. - Special Call | |
| May. 10 | ProKidney Q1 Loss Unchanged From Year Earlier | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 204M |
|---|---|---|---|---|---|
| Net income 2024 * | -146M | Net income 2025 * | -43M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 193M | Net cash position 2025 * | 310M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.5
x | P/E ratio 2025 * |
-4.45
x | Employees | 163 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProKidney Corp.
More recommendations
More press releases
| 1 day | +14.64% | ||
| 1 week | +5.75% | ||
| Current month | +5.75% | ||
| 1 month | +52.07% | ||
| 3 months | +121.02% | ||
| 6 months | +104.44% | ||
| Current year | +106.74% |
1 week
3.00
3.94
1 month
2.604.44
Current year
1.184.44
1 year
1.1213.51
3 years
1.1214.19
5 years
1.1214.19
10 years
1.1214.19
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Culleton
CEO | Chief Executive Officer | 57 | 23-07-16 |
James Coulston
DFI | Director of Finance/CFO | 48 | 21-12-31 |
Joseph Stavas
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Doyle
BRD | Director/Board Member | 61 | 21-12-31 |
Brian Pereira
BRD | Director/Board Member | 65 | 21-12-31 |
Alan Lotvin
BRD | Director/Board Member | 62 | 21-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 3.19 | -11.39% | 298,572 |
| 24-06-06 | 3.6 | -2.17% | 479,931 |
| 24-06-05 | 3.68 | +14.64% | 689,172 |
| 24-06-04 | 3.21 | +5.94% | 460,721 |
| 24-06-03 | 3.03 | -12.93% | 748,330 |
End-of-day quote Nasdaq, June 04, 2024
More quotes
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patientâs own cells isolated from the patient intended for treatment. The Companyâs lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patientâs diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patientâs own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participantâs own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.19
USD
Average target price
6.333
USD
Spread / Average Target
+98.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +106.74% | 204M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- PROK Stock
